Stigmasterol was reported to attenuate diabetic activity by targeting the glucose transporter protein type-4 (GLUT4) and alleviating nonalcoholic fatty liver disease (NAFLD) by altering the lipid metabolism in mice fed a high-fat western-style diet37. The gene discussed is SLC2A4; the disease is metabolic dysfunction-associated steatotic liver disease.